



Clinical Test Report

	Name Jane Doe	Sex Female	Date of Birth 08/11/87
Patient	Patient ID 10-259-0472	Height 5 ft 6 in	Weight 173 lbs
	Fasting Status Unknown	Age 31	BMI 28

	Collection Date	Specimen ID
en	10/10/18	1001011000001
Specimen	O8:57 AM	Report Type Original
	Received Date	Report Date



Diagnosis:


Dominant: Emotional Hunger (50%) Secondary: Hungry Gut (30%)

Treatment Considerations:

Treatment plan oriented around counseling to reduce emotional and stress eating with medication to help quell appetite between healthy meals. Plan detailed on PhenoTest Portal.

Prognosis:

Highly treatable



About Obesity Phenotypes:



Hungry Brain (50%): The brain's inability to determine when a meal is over is the main cause of obesity with this phenotype, which is also known as abnormal satiation. The good news is that, once this is acknowledged, you can implement strategies to help limit your intake during meals. Different interventions work by targeting neurotransmitters that are related to brain-gut signaling and your doctor can help you determine if these are right for you.



Hungry Gut (30%): Feeling hungry sooner or in periods between meals is frequently caused by your stomach and gut sending empty signals to your brain; this is also known as abnormal satiety. Helping the gut to know to wait is the key to reducing weight with this phenotype and some interventions are designed to help block these early hungry signals.



Emotional Hunger (15%): People who respond to this phenotype tend to seek food as a reaction to negative or positive emotions; this is also known as emotional eating. Once you improve your ability to manage these emotions, you're on the right track for weight reduction. Cognitive therapy and medications that address some of the underlying emotions can be very helpful and lead to weight loss for individuals with this phenotype.



Slow Burn (5%): With this phenotype, your metabolic rate is lower than normal; this is also known as abnormal energy expenditure. Understanding the underlying condition that is making your energy expenditure inefficient is essential to address this problem. In this phenotype, most effective strategy for weight reduction is to increase activity and implementing an effective exercise routine.









Test Results

The following test results were produced from the samples submitted to and analyzed by Phenomix Sciences, LLC. These sesults were interpreted and annotated according to obesity phenotype with applicable treatment considerations. Other clinical factors are not considered.

	Gene	rs ID	HGVS	Genotype Result
.8	FTO	rs9939609	NG_012969.1:g.87653T>A	Homozygous TT
aly	UCP3	rs1626521	NG_011515.1:g.10944C>T	Homozygous CC
S A	5-HT2CR	rs3813929	NG_012082.2:g.4963C>T	Heterozygous CT
Genomic Analysis	GNB3	rs5443	NG_009100.1:g.10501C>T	Homozygous CC
Ben	ADRA2a	rs1800544	NG_012020.1:g.4714G>C	Homozygous CC
	MC4R	rs17782313	NC_000018.9:g.57851097T>C	Heterozygous CT

cystathionine1 Glycine	3 μmol/L	0 - 5 μmol/L
Glycine	4.00	
	120 µmol/L	120 - 450 μmol/L
Valine	300 µmol/L	100 - 300 μmol/L
serotonin	220 ng/mL	50-220 ng/mL
glutamicacid	10 μmol/L	10 - 120 μmol/L
tryptophan	30 μmol/L	30 - 100 μmol/L
histidine	50 μmol/L	50 - 110 μmol/L
methylhistidine1	70 μmol/L	70 - 120 μmol/L
methionine	14 µmol/L	14 - 50 μmol/L
isocaproic	0 μmol/L	0 - 0 μmol/L
hydroxylysine2	4 μmol/L	0 - 5 μmol/L
ethanolamine	2 μmol/L	0 - 15 μmol/L
hydroxyproline	5 µmol/L	0 - 55 μmol/L
gamma.amino.n.butyricacid	µmol/L	0 - 2 μmol/L
threonine	55 µmol/L	60 - 200 μmol/L
alpha.aminoadipicacid	1 μmol/L	0 - 3 μmol/L
sarcosine	5 µmol/L	0 - 5 μmol/L
Arginine	45 µmol/L	40 - 160 μmol/L
Proline	99 µmol/L	90 - 330 μmol/L
Ghrelin	400 μmol/L	520 - 700 pg/mL
PYY	40 μmol/L	30-120 pg/mL
	Valine serotonin glutamicacid tryptophan histidine methylhistidine1 methionine isocaproic hydroxylysine2 ethanolamine hydroxyproline gamma.amino.n.butyricacid threonine alpha.aminoadipicacid sarcosine Arginine Proline Ghrelin	Valine serotonin glutamicacid tryptophan histidine methylhistidine1 isocaproic hydroxylysine2 ethanolamine hydroxyproline gamma.amino.n.butyricacid threonine alpha.aminoadipicacid Arginine Proline Ghrelin 300 µmol/L 220 ng/mL 20 ng/mL 10 µmol/L 50 µmol/L 70 µmol/L 44 µmol/L 5 µmol/L 55 µmol/L 45 µmol/L 45 µmol/L 45 µmol/L 45 µmol/L 470 99 µmol/L 400 µmol/L











Methodology and Limitations

Analytical results were produced using tests developed and validated by Phenomix Sciences, LLC, a clinical laboratory located at 9876 Main Street Suite 100 Minneapolis, MN 55405. These tests have not been cleared or approved by the U.S. Food and Drug Administration. Phenomix is certified under CLIA-88 and accredited by the College of American Pathologists as qualified to perform high-complexity testing. This tested is used for clinical purposes and should not be regarded as investigational or for research.

Quantitative metabolomic analysis is performed by extracting analytes from serum or plasma and then detecting using liquid chromatography mass spectrometry (LC-MS). The concentrations of each analyte are established by comparison of their ion intensity to that of their respective internal standards. Assays may be subject to general interference by factors such as inhibitors. Results of amino acid profiling should be interpreted in the context of clinical presentation, as well as other laboratory tests. Frozen serum and plasma may be diagnostic, however, certain amino acids may be falsely elevated or low than actual physiological conditions.

Qualitative genomic analysis is performed by extracting genomic DNA from whole blood, PCR amplification and detection of variants using hydrolysis probe-based chemistry (Thermo Fisher or LGC Biosearch Technologies). Assays may be subject to general interference by factors such as inhibitors and low quality or quantity of DNA. When present, the interferences typically yield no result rather than an inaccurate one. Infrequent polymorphisms in primer or probe binding regions may also affect testing and could produce an erroneous call or assay failure.

Test results may be inaccurate for individuals who have undergone or are receiving non-autologous blood transfusions, tissue, and/or organ transplant therapies. Although rare, results could also be impacted by other factors not addressed above such as laboratory error.

Due to the complexity of interpreting genetic results, such as those that may carry a probabilistic risk of disease, patients and providers should consider the benefits of consulting with trained genetic counseling professional when appropriate.



